We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
-8.08%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$310M
AUM Growth
-$33.3M
Cap. Flow
+$15.2M
Cap. Flow %
4.9%
Top 10 Hldgs %
97.66%
Holding
19
New
2
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ABEO icon
Abeona Therapeutics
ABEO
+$6.89M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$5.87M
3
LSTA icon
Lisata Therapeutics
LSTA
+$2.48M
4
EVOK
Evoke Pharma
EVOK
+$11.1K

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.4K

Sector Composition

Rank Sector Weight
1 Healthcare 18.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$251M 80.96%
4,397,838
– –
TOVX icon
2
Theriva Biologics
TOVX
$10.2M
$9.69M 3.12%
389
– –
AMPE
3
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$8.1M 2.61%
11,294
– –
ARCT icon
4
Arcturus Therapeutics
ARCT
$157M
$7.29M 2.35%
159,331
– –
ABEO icon
5
Abeona Therapeutics
ABEO
$345M
$6.88M 2.22%
54,391
+45,867
+538% +$6.89M
ADXS
6
DELISTED
Advaxis Inc
ADXS
$5.59M 1.8%
18,333
– –
CRBP icon
7
Corbus Pharmaceuticals
CRBP
$170M
$5.39M 1.74%
+58,333
New +$5.87M
LUMO
8
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.54M 1.46%
11,382
– –
ENLV icon
9
Enlivex Ltd
ENLV
$70.7M
$2.33M 0.75%
564
– –
KERX
10
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2M 0.64%
200,000
– –
LSTA icon
11
Lisata Therapeutics
LSTA
$15.2M
$1.87M 0.6%
+6,667
New +$2.48M
ADXSW
12
DELISTED
Advaxis Inc Warrants
ADXSW
$1.75M 0.56%
112,500
– –
ALDX icon
13
Aldeyra Therapeutics
ALDX
$91.7M
$1.05M 0.34%
135,800
– –
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.23B
$890K 0.29%
97,100
-2,900
-3% -$32.4K
GLMD icon
15
Galmed Pharmaceuticals
GLMD
$3.94M
$654K 0.21%
361
– –
NBSE
16
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$515K 0.17%
513
– –
EVOK
17
DELISTED
Evoke Pharma
EVOK
$291K 0.09%
387
+13
+3% +$11.1K
ZSAN
18
DELISTED
Zosano Pharma Corporation
ZSAN
$145K 0.05%
29
– –
APTO
19
DELISTED
Aptose Biosciences, Inc.
APTO
$102K 0.03%
44
– –

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Knoll Capital Management held 19 positions worth $310M, down 9.7% from $343M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Knoll Capital Management deployed $15.2M of net new capital in Q2 2015, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Corbus Pharmaceuticals: 58,333 shares worth $5.39M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $32.4K trimmed.

  • Knoll Capital Management's largest Q2 2015 buy was Corbus Pharmaceuticals: 58,333 shares worth $5.39M.
  • Knoll Capital Management added most to Abeona Therapeutics in Q2 2015, an estimated $6.89M increase.
  • Knoll Capital Management's biggest Q2 2015 reduction was Iovance Biotherapeutics, cutting an estimated $32.4K.
  • Knoll Capital Management's ten largest holdings make up 98% of its $310M portfolio in Q2 2015.
  • Knoll Capital Management opened 2 new positions and closed 0 in Q2 2015.
  • Knoll Capital Management's portfolio value fell 9.7% quarter-over-quarter to $310M.

Based on Knoll Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.